1-3 of 3
Patrice Eric Nasnas
Close
Sort by
Journal Articles

Impact of High-Risk Cytogenetics (HR-CTG) on the Outcome of Newly Diagnosed Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Frontline Blinatumomab (Blina) and/or Inotuzumab Ozogamicin (Ino) Containing Hypercvad (HCVAD) Therapy

Jayastu Senapati, Elias Jabbour, Nicholas J. Short, Guilin Tang, Fadi G. Haddad, Nitin Jain, Ghayas C. Issa, Tapan M. Kadia, Naval Daver, Alessandra Ferrajoli, Monica Kwari, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Patrice Eric Nasnas, Naveen Pemmaraju, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 1500.
https://doi.org/10.1182/blood-2023-181379
Published: 2023
Journal Articles

Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML)

Fadi G. Haddad, Elias Jabbour, Koji Sasaki, Lewis Nasr, Xuelin Huang, Ghayas C. Issa, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia, Naval Daver, Yesid Alvarado Valero, Cedric Nasnas, Maro Ohanian, Nicholas J. Short, Lucia Masarova, Marianne Zoghbi, Patrice Eric Nasnas, Guillermo Montalban-Bravo, Jeffrey Skinner, Sherry Pierce, Michael Andreeff, Hagop M. Kantarjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 870.
https://doi.org/10.1182/blood-2023-188236
Published: 2023
Journal Articles

Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II Trial

Fadi G. Haddad, Elias Jabbour, Nicholas J. Short, Nitin Jain, Xuelin Huang, Guillermo Montalban-Bravo, Tapan M. Kadia, Naval Daver, Cedric Nasnas, Ejiroghene Mayor, Patrice Eric Nasnas, Wuliamatu Deen, Marianne Zoghbi, Jennifer Thankachan, Christopher Loiselle, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 2827.
https://doi.org/10.1182/blood-2023-188064
Published: 2023